Abstract
The present investigation was conducted to examine the effects of combination chemotherapy including Cyclophosphamide (CPM), THP-adriamycin (THP), and Cisplatin (CDDP) (CTP regimen) on the development of urinary bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) in rats compared with CPM, adriamycin (ADM), and CDDP (CAP regimen). One hundred fiftyone male F344 rats were divided into 7 groups: Group 1 (BBN treatment alone), Group 2 (BBN treatment followed by CAP), Group 3 (BBN treatment followed by CTP), Group 4 (CAP without BBN treatment), Group 5 (CTP without BBN treatment), Group 6 (saline treatment alone), and Group 7 (untreated controls). All rats were sacrified 24 weeks after the beginning of the experiment. Bladder carcinoma was observed only in Groups 1 through 3. The incidence of carcinoma did not significantly differ between any two of these three groups, 29/30 (97%) for Group 1, 16/18 (89%) for Group 2, and 25/29 (86%) for Group 3. The grade and stage of the carcinoma were not suppressed by either treatment. The mean number of tumors was significantly lower in Group 3 than those in Group 1 (P<0.01) and in Group 2 (P<0.05). Renal changes were most marked and both CTP and CAP treatment groups showed proliferation of renal tubules and appearance of giant cells. No cardiotoxicity was observed in Group 5 although changes such as myocardiac fibrosis were observed in Group 4. These results suggest that THP is useful in the combination chemotherapy for invasive bladder cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have